PMID- 37156410
OWN - NLM
STAT- MEDLINE
DCOM- 20230620
LR  - 20230622
IS  - 1532-8600 (Electronic)
IS  - 0026-0495 (Linking)
VI  - 144
DP  - 2023 Jul
TI  - Diet, exercise, and pharmacotherapy for sarcopenia in people with diabetes.
PG  - 155585
LID - S0026-0495(23)00188-9 [pii]
LID - 10.1016/j.metabol.2023.155585 [doi]
AB  - Diabetes prevalence is increasing rapidly in older people, and sarcopenia is 
      prevalent as a novel complication, particularly in patients with type 2 diabetes 
      mellitus (T2DM). Therefore, sarcopenia prevention and treatment in these people 
      is necessary. Diabetes accelerates sarcopenia through several mechanisms, such as 
      hyperglycemia, chronic inflammation and oxidative stress. The effects of diet, 
      exercise, and pharmacotherapy on sarcopenia in patients with T2DM need to be 
      considered. In diet, low intake of energy, protein, vitamin D, and omega-3 fatty acid 
      are associated with sarcopenia risk. In exercises, although intervention studies 
      in people, especially older and non-obese patients with diabetes, are few, 
      accumulating evidence shows the usefulness of exercise, particularly resistance 
      exercise for muscle mass and strength, and aerobic exercise for physical 
      performance in sarcopenia. In pharmacotherapy, certain classes of anti-diabetes 
      compounds have possibility of preventing sarcopenia. However, much data on diet, 
      exercise, and pharmacotherapy were obtained in obese and non-elderly patients 
      with T2DM, demanding actual clinical data on non-obese and older patients with 
      diabetes.
CI  - Copyright (c) 2023 Elsevier Inc. All rights reserved.
FAU - Hashimoto, Yoshitaka
AU  - Hashimoto Y
AD  - Department of Endocrinology and Metabolism, Kyoto Prefectural University of 
      Medicine, Graduate School of Medical Science, Kyoto, Japan; Department of 
      Diabetes and Endocrinology, Matsushita Memorial Hospital, 5-55 Sotojima-cho, 
      Moriguchi 570-8540, Japan. Electronic address: y-hashi@koto.kpu-m.ac.jp.
FAU - Takahashi, Fuyuko
AU  - Takahashi F
AD  - Department of Endocrinology and Metabolism, Kyoto Prefectural University of 
      Medicine, Graduate School of Medical Science, Kyoto, Japan.
FAU - Okamura, Takuro
AU  - Okamura T
AD  - Department of Endocrinology and Metabolism, Kyoto Prefectural University of 
      Medicine, Graduate School of Medical Science, Kyoto, Japan.
FAU - Hamaguchi, Masahide
AU  - Hamaguchi M
AD  - Department of Endocrinology and Metabolism, Kyoto Prefectural University of 
      Medicine, Graduate School of Medical Science, Kyoto, Japan.
FAU - Fukui, Michiaki
AU  - Fukui M
AD  - Department of Endocrinology and Metabolism, Kyoto Prefectural University of 
      Medicine, Graduate School of Medical Science, Kyoto, Japan.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20230506
PL  - United States
TA  - Metabolism
JT  - Metabolism: clinical and experimental
JID - 0375267
RN  - 0 (Vitamins)
SB  - IM
MH  - Humans
MH  - Aged
MH  - Middle Aged
MH  - *Sarcopenia/drug therapy/etiology
MH  - *Diabetes Mellitus, Type 2/complications/therapy
MH  - Diet
MH  - Exercise
MH  - Vitamins
MH  - Muscle Strength
MH  - Muscle, Skeletal/physiology
OTO - NOTNLM
OT  - Aged
OT  - Diabetes
OT  - Diets
OT  - Exercise
OT  - Lifestyles
OT  - Medication
OT  - Muscle mass
OT  - Older
OT  - Sarcopenia
COIS- Declaration of competing interest Dr. Hashimoto reports personal fees from Novo 
      Nordisk Pharma Ltd., Sanofi K.K., Mitsubishi Tanabe Pharma Corp., Ono Pharma Co. 
      Ltd., Nippon Boehringer Ingelheim Co. Ltd., Kowa Pharma Co. Ltd., and Sumitomo 
      Dainippon Pharma Co. Ltd. Dr. Hamaguchi received grants from Daiichi Sankyo Co. 
      Ltd., Nippon Boehringer Ingelheim Co. Ltd., Astellas Pharma Inc., Mitsubishi 
      Tanabe Pharma Corp., Novo Nordisk Pharma Ltd., Sanofi K.K., Takeda Pharma Co. 
      Ltd., Sumitomo Dainippon Pharma Co. Ltd., Asahi Kasei Pharma, Kyowa Kirin Co. 
      Ltd., and Eli Lilly Japan K.K. outside the submitted work. Prof. Fukui received 
      grants from Taisho Pharma Co., Ltd., Mitsubishi Tanabe Pharma Corp, Novo Nordisk 
      Pharma Ltd., Ono Pharma Co. Ltd., Kowa Pharma Co. Ltd., Sanofi K.K., Nippon 
      Boehringer Ingelheim Co. Ltd., Daiichi Sankyo Co. Ltd., Kissei Pharma Co. Ltd., 
      MSD K.K., Kyowa Kirin Co., Ltd., Sumitomo Dainippon Pharma Co., Ltd., Eli Lilly 
      Japan K.K., Tejin Pharma Ltd., Takeda Pharma Co. Ltd., Nippon Chemiphar Co., 
      Ltd., Astellas Pharma Inc., Abbott Japan Co. Ltd., Sanwa Kagagu Kenkyusho CO., 
      LtD., Johnson & Johnson k.k. Medical Co., and Terumo Corp., and received 
      honoraria from AstraZeneca K.K., Taisho Pharma Co., Ltd., Ono Pharma Co. Ltd., 
      Novo Nordisk Pharma Ltd., Sanofi K.K., Teijin Pharma Ltd., Takeda Pharma Co. 
      Ltd., Astellas Pharma Inc., MSD K.K., Mitsubishi Tanabe Pharma Corp., Eli Lilly 
      Japan K.K., Kissei Pharma Co., Ltd., Sumitomo Dainippon Pharma Co. Ltd., Daiichi 
      Sankyo Co. Ltd., Mochida Pharma Co. Ltd., Kowa Pharma Co. Ltd., Arkray Inc., 
      Abbott Japan Co. Ltd., Sanwa Kagaku Kenkyusho Co. Ltd., Kyowa Kirin Co. Ltd., 
      Nippon Boehringer Ingelheim Co., Ltd., Medtronic Japan Co. Ltd., Bayer Yakuhin, 
      Ltd., and Nipro Corp. outside the submitted work. The other authors declare no 
      conflict of interest.
EDAT- 2023/05/09 00:42
MHDA- 2023/06/20 06:42
CRDT- 2023/05/08 19:22
PHST- 2023/01/24 00:00 [received]
PHST- 2023/04/17 00:00 [revised]
PHST- 2023/05/01 00:00 [accepted]
PHST- 2023/06/20 06:42 [medline]
PHST- 2023/05/09 00:42 [pubmed]
PHST- 2023/05/08 19:22 [entrez]
AID - S0026-0495(23)00188-9 [pii]
AID - 10.1016/j.metabol.2023.155585 [doi]
PST - ppublish
SO  - Metabolism. 2023 Jul;144:155585. doi: 10.1016/j.metabol.2023.155585. Epub 2023 
      May 6.